Invivyd, Inc. (IVVD)
Adagio Therapeutics, Inc., a biopharmaceutical firm in its clinical development phase, operates within the United States, specializing in the discovery, progression, and marketing of antibody-derived solutions for infectious diseases. The company's leading drug candidate, ADG20 (adintrevimab), is a neutralizing antibody currently undergoing Phase 3 clinical investigation for both the management and prevention of coronavirus disease. Adagio Therapeutics maintains collaborative agreements with Adimab, LLC to facilitate the identification and enhancement of its exclusive antibodies. Furthermore, it partners with the Scripps Research Institute to conduct studies aimed at uncovering potential vaccine solutions for the prophylaxis, detection, or therapy of influenza or beta coronaviruses. Incorporated in 2020, the company's base of operations is in Waltham, Massachusetts.
Sector: Biological Products, (No Diagnostic Substances)
Industry: Biotechnology
Invivyd, Inc.
NASDAQ:IVVDHealthcare · Biotechnology
-3.37%$0.5817
AH$0.6048+3.97%vs close
Mkt Cap$171.8M
Float246.76M
O/S295.34M
Vol
$ Vol
RVOL
Inst Own78.7%
SI15.0%
Earnings
Dilution
Financials Summary
Revenue$53.43M
Net Income-$52.49M
Total Assets$276.88M
Free Cash Flow-$58.29M
Debt & Equity
Debt 1%
Equity 99%
Total Debt$2.49M
Total Equity$241.54M
Shares Outstanding
Short Interest
Split History
No splits on record
Nothing in IVVD's public trading history: no forward or reverse split has affected the share count.
Balance Sheet Details
Assets$276.88M
Liabilities$35.34M
Accounts Receivable$14.6M
Accounts Payable$13.74M
Inventory$25.5M
PP&E (Net)$3.81M
Goodwill$0
Intangible Assets$0
Income Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Revenue | $53.43M | $25.38M | $0 | $0 | $0 | $0 |
| YoY Growth | 110.5% | - | - | - | - | - |
| Cost of Revenue | $3.75M | $1.62M | $0 | $0 | $0 | $0 |
| Gross Profit | $49.68M | $23.77M | $0 | $0 | $0 | $0 |
| Gross Margin | 93.0% | 93.6% | - | - | - | - |
| Research and Development | $38.31M | $137.25M | $158.66M | $179.21M | $182.89M | $106.49M |
| Selling, General, and Administrative | $66.93M | $63.39M | $49.13M | $47.04M | $36.52M | $5.5M |
| Other | $0 | $0 | $4.97M | $21.77M | $7.5M | $0 |
| Total Operating Expenses | $105.24M | $200.64M | $212.76M | $248.03M | $226.91M | $111.99M |
| Operating Income (EBIT) | -$55.56M | -$176.88M | -$212.76M | -$248.03M | -$226.91M | -$111.99M |
| Operating Margin | -104.0% | -696.8% | - | - | - | - |
| Interest Expense | $0 | $0 | $0 | $43.08M | $0 | $0 |
| Interest Income | $0 | $6.95M | $0 | $6.71M | $0 | $8K |
| Other Income (Expense) | $3.07M | $6.95M | $14.12M | $6.71M | $118K | $14K |
| Income Before Tax (EBT) | -$52.49M | -$169.93M | -$198.64M | -$241.32M | -$226.79M | -$111.98M |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$52.49M | -$169.93M | -$198.64M | -$241.32M | -$226.79M | -$111.98M |
| Net Income Margin | -98.2% | -669.4% | - | - | - | - |
| Supplementary Data | ||||||
| EPS | -0.30 | -1.43 | -1.81 | -2.17 | -2.11 | -0.59 |
| Diluted EPS | -0.30 | -1.43 | -1.81 | -2.17 | -2.11 | -0.59 |
| Weighted Average OS | 172.21M | 118.56M | 109.53M | 108.27M | 110.78M | 111.25M |
| EBITDA | -$50.38M | -$166.81M | -$205.75M | -$225.8M | -$219.41M | $0 |
| EBITDA Margin | -94.3% | -657.2% | - | - | - | - |
Balance Sheet
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Assets | ||||||
| Current Assets | ||||||
| Cash and Cash Equivalents | $226.69M | $69.35M | $200.64M | $92.08M | $542.22M | $114.99M |
| Short-Term Investments | $0 | $0 | $0 | $279.92M | $49.19M | $0 |
| Cash and Short-Term Investments | $226.69M | $69.35M | $200.64M | $371.99M | $591.42M | $114.99M |
| Accounts Receivable | $14.6M | $11.17M | $933K | $377K | $229K | $0 |
| Inventory | $25.5M | $0 | $0 | $0 | $0 | $0 |
| Other Current Assets | -$23.78M | $0 | $0 | $0 | $0 | $0 |
| Total Current Assets | $247.47M | $100.68M | $224.88M | $376.92M | $616.71M | $117.38M |
| Long-Term Assets | ||||||
| Property, Plant & Equipment Net | $3.81M | $2.89M | $4.13M | $6.06M | $83K | $0 |
| Goodwill | $0 | $0 | $0 | $0 | $0 | $0 |
| Intangible Assets | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 |
| Deferred Tax Assets | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Assets | $25.61M | $25.94M | $175K | $191K | $3.3M | $0 |
| Total Long-Term Assets | $29.42M | $28.83M | $4.3M | $6.25M | $3.38M | $0 |
| Other Assets | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Assets | $276.88M | $129.51M | $229.18M | $383.17M | $620.09M | $117.38M |
| Liabilities | ||||||
| Current Liabilities | ||||||
| Accounts Payable | $13.74M | $10.45M | $7.95M | $1.52M | $5.78M | $8.15M |
| Short-Term Debt | $0 | $0 | $0 | $0 | $0 | $0 |
| Current Income Tax Payable | $0 | $0 | $0 | $0 | $0 | $0 |
| Current Unearned Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Current Liabilities | $5.8M | $3.94M | $10.79M | $6.03M | $4.95M | $794K |
| Total Current Liabilities | $34.16M | $61.98M | $50.29M | $25.03M | $62.06M | $13.07M |
| Long-Term Liabilities | ||||||
| Long-Term Debt | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Unearned Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Deferred Tax Liabilities | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Liabilities | $0 | $0 | $700K | $1K | $12K | $169.56M |
| Total Long-Term Liabilities | $1.18M | $0 | $1.42M | $2.17M | $12K | $169.56M |
| Other Liabilities | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $35.34M | $61.98M | $51.71M | $27.2M | $62.07M | $182.63M |
| Stockholders' Equity | ||||||
| Preferred Stock | $0 | $0 | $0 | $0 | $0 | $0 |
| Common Stock | $28K | $12K | $11K | $11K | $11K | $1K |
| Retained Earnings | -$954.48M | -$901.99M | -$732.07M | -$533.43M | -$292.11M | -$65.32M |
| Comprehensive Income & Other | -$41K | -$5K | -$13K | -$272K | -$8K | $0 |
| Other Stockholders' Equity | $1.2B | $969.52M | $909.53M | $889.38M | $850.12M | $69K |
| Total Equity | $241.54M | $67.54M | $177.47M | $355.97M | $558.02M | -$65.25M |
| Minority Interest | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities and Equity | $276.88M | $129.51M | $229.18M | $383.17M | $620.09M | $117.38M |
| Supplementary Data | ||||||
| Total Debt | $2.49M | $1.3M | $2.17M | $3.72M | $0 | $0 |
| Net Debt | -$224.19M | -$68.05M | -$198.48M | -$88.35M | -$542.22M | -$114.99M |
Cash Flow Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Operating Activities | ||||||
| Net Income | -$52.49M | -$169.93M | -$198.64M | -$241.32M | -$226.79M | -$65.32M |
| Depreciation & Amortization | $2.11M | $3.11M | $2.03M | $462K | $1K | $43.2M |
| Deferred Income Tax | $0 | $0 | $0 | $0 | $0 | $0 |
| Stock-Based Compensation | $11.64M | $19.79M | $18.68M | $21.65M | $17.76M | $0 |
| Changes in Working Capital: | ||||||
| Accounts Receivable | -$3.34M | -$10.91M | $0 | $0 | $0 | $0 |
| Inventory | -$373K | -$24.89M | $0 | $0 | $0 | $0 |
| Accounts Payable | $3.21M | $2.42M | $6.47M | -$4.3M | -$2.37M | $0 |
| Other Working Capital | -$19.2M | $9.9M | -$583K | -$11.83M | $25.16M | $10.68M |
| Total Working Capital Change | -$19.69M | -$23.47M | $5.89M | -$16.13M | $22.79M | $10.68M |
| Other Non-Cash Items | $298K | $0 | -$1.12M | $15.35M | $1.5M | -$3.13M |
| Net Cash from Operating | -$58.13M | -$170.49M | -$173.16M | -$219.99M | -$184.74M | -$14.57M |
| Investing Activities | ||||||
| Capital Expenditures | -$155K | -$140K | -$615K | -$1.71M | -$84K | $0 |
| Acquisitions | $0 | $0 | $0 | $0 | $0 | $0 |
| Purchases of Investments | $0 | $0 | -$91.2M | -$297.96M | -$188.63M | $0 |
| Sales of Investments | $0 | $0 | $372.5M | $69M | $138M | $0 |
| Other Investing Activities | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Cash from Investing | -$155K | -$140K | $280.68M | -$230.67M | -$50.71M | $0 |
| Financing Activities | ||||||
| Debt Repaid | - | - | - | - | - | - |
| Common Stock Issuance | $215.63M | $39.93M | $1.2M | $510K | $330.9M | $129.56M |
| Common Stock Repurchases | $0 | $0 | -$1K | -$4K | $0 | -$3K |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Financing Activities | $0 | -$597K | -$149K | $0 | -$3.38M | $0 |
| Net Cash from Financing | $215.63M | $39.33M | $1.04M | $506K | $662.68M | $129.56M |
| Forex Effect | $0 | $8K | $0 | $0 | $0 | $0 |
| Net Change in Cash | $157.34M | -$131.29M | $108.56M | -$450.15M | $427.24M | $114.99M |
| Supplementary Data | ||||||
| Operating Cash Flow | -$58.13M | -$170.49M | -$173.16M | -$219.99M | -$184.74M | -$14.57M |
| Capital Expenditure | -$155K | -$140K | -$615K | -$1.71M | -$84K | $0 |
| Free Cash Flow | -$58.29M | -$170.63M | -$173.78M | -$221.69M | -$184.82M | -$14.57M |
| Cash at Beginning | $69.35M | $200.64M | $92.08M | $542.22M | $114.99M | $0 |
| Cash at End | $226.69M | $69.35M | $200.64M | $92.08M | $542.22M | $114.99M |